Recently, Henlius’ self-developed and manufactured HANQUYOU (trastuzumab, trade names: Zercepac® in Europe, Tuzucip® and Trastucip® in Australia) has been approved for marketing in Thailand and the Philippines under the trade names of TRAZHER® and Hertumab®, respectively, for the treatment of HER2-positive breast cancer and gastric cancer. Up to now, HANQUYOU has been successfully approved in Southeast Asian countries, including Singapore and Cambodia, and in a total of more than 40 countries and regions. Breast cancer is the most prevalent malignancy in Southeast Asia, with nearly 170,000 new cases of breast cancer in the region in 2022. About 15% to 20% of breast tumours are HER2-positive breast cancers. On the other hand, the reported rates of HER2 positivity in patients with gastric cancer range from 12% to 23%. Trastuzumab has long been a cornerstone of therapy for the treatment of HER2-positive breast and gastric cancers, and has been included as a ...
According to the latest data, the population of the Philippines has exceeded 100 million, and the demand for various types of medicine shows a steady increase. With the advancement of relations between China and the Philippines and collaborations in economy and trade, the Philippines has become a prime exporting country for Chinese pharmaceutical companies.
Sanofi has refused both requests from the Government of the Philippines to refund used doses of its Dengvaxia vaccine as well as the costs of medical treatment of first-time dengue patients who were harmed after its use in the nation’s vaccination programme of 837,000 children.
A world-first dengue vaccination programme in the Philippines that was suspended over safety concerns will not cause anyone who was immunised to die, drug manufacturer Sanofi and local authorities said on Monday
The Philippines has suspended the sale and distribution of Sanofi’s dengue vaccine, authorities said on Tuesday, after the French pharmaceutical giant last week warned it could worsen symptoms for people who had not previously been infected.
Recently, HANQUYOU (trastuzumab, trade name in Europe: Zercepac®), independently developed and manufactured by Henlius, has been approved to be marketed in Brazil for the treatment of HER2-positive breast cancer and gastric cancer. To date, the product has been approved for marketing in more than 40 countries and regions worldwide. Following the commercialization of HANQUYOU in Argentina, the approval of HANQUYOU in Brazil, the largest economy and the most populous country in Latin America, has become another anchor point for Henlius’ continuous global commercial expansion. Latin America and the Caribbean comprises 33 countries and regions with a total population of close to 660 million as of 2022 and a per capita GDP of close to $10,000 per capita [1]. In Latin America, breast and gastric cancers are the most and fifth most prevalent malignancies, respectively. The total number of new cases of breast and gastric cancer in the region in 2022 ...
On February 2, 2024, a batch of trivalent influenza vaccine Anflu® produced by SINOVAC arrived in Santiago, Chile. This is the first time that SINOVAC influenza vaccines have exported finished influenza vaccines prepared from the candidate strains recommended by the World Health Organization for influenza vaccines in the southern hemisphere to a country in the southern hemisphere. The vaccine will be distributed to private vaccination centers in Santiago and other major cities across the country for the local 2024 Southern Hemisphere Influenza Season vaccination campaign starting in March. Bárbara Ester Orellana Álvarez, SINOVAC’s Director of Registration in Chile, said the vaccine is now safely stored in cold storage under license from the Chilean Institute of Public Health (ISP). The timely arrival of this shipment demonstrates SINOVAC’s commitment to providing the Chilean people with vaccines of the highest quality and safety standards. “We are confident that this operation will contribute to ...
At the kick-off meeting held at the Center for Disease Control and Prevention in Pu’er City, Yunnan Province, regarding the REC610 China Phase I clinical trial project, the investigator introduced the background of the disease, information about the REC610 product, and gave a detailed introduction of the overall design of the clinical trial, the trial process, and the precautions and other aspects of the clinical trial. After the meeting, the research team sorted out the trial process to support the smooth development of the subsequent trial. REC610 carries a novel adjuvant, BFA01, developed by the Company, which promotes the production of high levels of VZV glycoprotein E (gE)-specific CD4+ T cells and antibodies, and is intended to be used for the prevention of herpes zoster in adults aged 40 years and above. Previously, data from an interim analysis of the FIH clinical trial of REC610 in the Philippines using GlaxoSmithKline ...
Today, UNITE4TB, an international public-private partnership striving to fast-track the development of innovative Tuberculosis (TB) treatments, announced the start of its phase 2B/C clinical trial program with the first participant enrolled at its trial site in Cape Town, South Africa. The announcement is a major milestone for the project and the TB community as a whole, helping to advance TB science and enhance the efficiency with which new treatments are delivered. The TB challenge TB is a major threat to public health, being among the leading causes of death worldwide. In 2021, the disease claimed the lives of 1.6 million people, making it the second leading infectious killer after COVID-19. Drug-resistant TB and long treatment regimens have increased the urgency for action and investment in TB research. For people affected by TB, the most important outcome is rapid access to better regimens of shorter treatment duration and with fewer side ...
Kezar Life Sciences and Everest Medicines have signed a partnership and licence agreement for the development and commercialisation of zetomipzomib for lupus nephritis (LN) in select territories. The territories covered under the agreement include Greater China, South Korea and South East Asia. As per the deal terms, Kezar is eligible to receive up to $132.5m in initial upfront and milestone payments contingent on meeting development, regulatory and commercialisation goals in the future. Kezar will also receive tiered royalty payments on net product sales from Everest. Everest will obtain sole rights for developing and marketing zetomipzomib in regions such as Greater China, Indonesia, Malaysia, the Philippines, Singapore, South Korea, Thailand and Vietnam. Everest will also collaborate with Kezar for the Phase IIb PALIZADE clinical trial of zetomipzomib, an immunoproteasome inhibitor of Kezar, in active LN patients in Greater China, South Korea and South East Asia. In the licensed territories, Everest will ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.